Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination

초록

Introduction: The UK implemented a single-dose HPV vaccination policy in September 2023, aiming for sustained protection, better vaccine coverage, and reduced healthcare costs. This research assesses the cost-effectiveness of both one-dose and two-dose schedules from a healthcare perspective. Methods: Using an age-structured dynamic model, the study analyzed long-term health and economic outcomes of these two different vaccination approaches. It focused on the effects of vaccinating 12- to 13-year-olds with the 9-valent HPV vaccine in either single-dose or two-dose regimens from 2023 to 2093. The analysis, conducted in 2023-2024, - 2024, explored different immunity durations (10, 30 years, or lifetime) and efficacy fi cacy levels for the single-dose strategy. Results: The study indicated that in the UK, vaccinating 12- to 13-year-olds with a two-dose regimen is not considered cost-effective compared to the single-dose option, assumed to be 90% as effective for 10 years. The incremental cost-effectiveness ratios for two doses ranged from 230,903 pound to 1,082,916 pound per quality-adjusted life year (QALY), significantly fi cantly exceeding the UK's ' s 20,000 pound/ QALY willingness-to-pay threshold. Over 70 years, a switch from a two-dose to a single-dose vaccination schedule could potentially lead to savings of over 1,073 pound million in the healthcare system. Furthermore, the single-dose regimen was cost-effective compared to no vaccination, with an incremental cost-effectiveness ratio below 2,040 pound/QALY. Conclusions: The study affirms fi rms the cost-effectiveness of the UK's ' s single-dose HPV vaccine, in sync with its September 2023 policy shift. The shift not only provides fi nancial benefits fi ts but also simplifies fi es vaccine administration, strategically reducing HPV's ' s epidemiological and economic impacts. Am J Prev Med 2024;67(2):231-240. - 240. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. This is an open access article under the CC BY-NC-ND license

키워드